Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, and Tolerability of Upadacitinib in Adult and Adolescent Subjects With Non-Segmental Vitiligo Who Are Eligible for Systemic Therapy

Next Previous
Trial Profile

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, and Tolerability of Upadacitinib in Adult and Adolescent Subjects With Non-Segmental Vitiligo Who Are Eligible for Systemic Therapy

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Feb 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Upadacitinib (Primary)
  • Indications Vitiligo
  • Focus Registrational; Therapeutic Use
  • Acronyms Viti-Up
  • Sponsors AbbVie

Most Recent Events

  • 03 Feb 2026 According to an AbbVie media release, company has submitted applications to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for a new indication for upadacitinib, supported by data from the phase 3 Viti-Up clinical studies.
  • 29 Oct 2025 Primary endpoint has been met (Percentage of Participants Achieving Facial-Vitiligo Area Scoring Index (F-VASI) 75 ( 75% Improvement in F-VASI From Baseline)), according to AbbVie media release.
  • 29 Oct 2025 Primary endpoint has been met (Percentage of Participants Achieving Total Vitiligo Area Scoring Index (T-VASI) 50 ( 50% Improvement in T-VASI From Baseline)), according to AbbVie media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top